MTX

研究成果: Review article査読

1 被引用数 (Scopus)

抄録

Methotrexate is an anchor drug in the management of rheumatoid arthritis (RA). MTX monotherapy is as effective as TNF inhibitor (TNFi) monotherapy, and can prevent joint destruction in 70% of Japanese early RA patients. Also, MTX in combination with TNFi is superior to MTX monotherapy or TNFi monotherapy. Many high quality clinical studies have proved that MTX should be added to biological agents irrespective of their mode of action in inducing remission. However, it also causes hepatotoxicity, bone marrow suppression, nausea, and so on. A question arises if the dose of MTX to maintain remission could be reduced once remission is achieved. The optimal dose and usage of methotrexate remains to clarify.

本文言語English
ページ(範囲)944-947
ページ数4
ジャーナルNihon rinsho. Japanese journal of clinical medicine
74
6
出版ステータスPublished - 2016 6 1

ASJC Scopus subject areas

  • Medicine(all)

フィンガープリント 「MTX」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル